Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, knocking down KLF6 expression significantly diminished the platelet-mediated enhancement of HCC growth.
|
28638139 |
2017 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The loss or reduction of KLF6 is linked to the progression of hepatocellular carcinoma, but its contribution to liver regeneration and repair in acute liver injury are lacking so far.
|
28808340 |
2017 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, our findings show that KLF6 suppresses growth and invasion of HCC cells in vitro and in vivo, suggesting a tumor suppressive function in HCC and provides the potential therapeutic target for the treatment of HCC.
|
27510817 |
2016 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our data demonstrate a novel function for KLF6 in constraining HCC dissemination through the regulation of a VAV3-RAC1 signaling axis.
|
26876204 |
2016 |
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because several colorectal cancer and hepatocellular carcinoma-derived KLF6 mutations affect a glycogen synthase kinase 3β (GSK3β) phosphorylation consensus site, we investigated the role of GSK3β in the regulation of KLF6 function.
|
23085750 |
2013 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Enhanced cell replication through increased KLF6 alternative splicing is a novel growth-promoting pathway of HGF that could contribute to the molecule's mitogenic activity in physiologic liver growth and hepatocellular carcinoma.
|
22859706 |
2012 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased KLF6 expression in human hepatocellular carcinoma (HCC) correlates with increased mortality, but the contribution of increased SV1 is unknown.
|
22535637 |
2012 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that KLF6 deficiency contributes significantly to the carcinogenic milieu in human and murine HCC and uncover a novel tumor suppressor activity of KLF6 in HCC by linking its transcriptional repression of Mdm2 to stabilizing p53.
|
21563203 |
2011 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An increased SV1/KLF6 mRNA ratio in HCC was already described.
|
20801538 |
2010 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tumor suppressor Kruppel-like factor 6 (KLF6) is frequently inactivated in hepatocellular carcinoma (HCC).
|
20116377 |
2010 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among them, Klf6 was down-expressed in all MN samples whereas it was over-expressed in cirrhosis and HCC.
|
18171345 |
2008 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In 67 human HCCs, there is a significant correlation between activated Ras signaling and increased KLF6 alternative splicing.
|
18471523 |
2008 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that reduced KLF6 expression is common in both HBV- and HCV-related HCCs and occurs at critical stages during cancer progression.
|
17196295 |
2007 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To confirm and extend the data obtained at RNA level, we performed detailed immunoblotting analysis on HCC tissues and hepatoma cell lines using a rabbit polyclonal antibody specific for KLF6.
|
17550140 |
2007 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that HCC, HepG2 and HuH7 cells expressed KLF6 messenger ribonucleic acid and protein.
|
17347668 |
2007 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
We found that HCC, HepG2 and HuH7 cells expressed KLF6 messenger ribonucleic acid and protein.
|
17347668 |
2007 |
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that genetic and epigenetic alteration of KLF6 may play a minor role in the development of HCC.
|
16872311 |
2006 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of KLF6 mRNA or protein was down-regulated in 8 (34.7%) or 9 (39.1%) of 23 HCC tissues.
|
16972326 |
2006 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Expression of KLF6 mRNA or protein was down-regulated in 8 (34.7%) or 9 (39.1%) of 23 HCC tissues.
|
16972326 |
2006 |
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
The results suggest that genetic and epigenetic alteration of KLF6 may play a minor role in the development of HCC.
|
16872311 |
2006 |
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, high frequency (42%) of KLF6 mutations have been reported in colorectal cancers (CRC) as in prostate cancers, astrocytic gliomas and hepatocellular carcinomas.
|
16044160 |
2005 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In conclusion, we propose that KLF6 is deregulated by loss and/or mutation in HCC, and its inactivation may contribute to pathogenesis in a significant number of these tumors.
|
15486921 |
2004 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, we propose that KLF6 is deregulated by loss and/or mutation in HCC, and its inactivation may contribute to pathogenesis in a significant number of these tumors.
|
15486921 |
2004 |